Novel |
CGREF1 |
cell growth regulator with EF-hand domain 1 |
|
|
|
Novel |
CHMP6 |
charged multivesicular body protein 6 |
- Budding and maturation of HIV virion
- Macroautophagy
- Endosomal Sorting Complex Required For Transport (ESCRT)
- HCMV Late Events
- Late endosomal microautophagy
- Sealing of the nuclear envelope (NE) by ESCRT-III
- Translation of Replicase and Assembly of the Replication Transcription Complex
- Translation of Replicase and Assembly of the Replication Transcription Complex
|
|
|
Novel |
IPP |
intracisternal A particle-promoted polypeptide |
|
|
|
Novel |
NRXN1 |
neurexin 1 |
- Neurexins and neuroligins
- Neurexins and neuroligins
- Non-integrin membrane-ECM interactions
- Neurexins and neuroligins
- Neurexins and neuroligins
|
- Calcium citrate
- Calcium Phosphate
- Calcium phosphate dihydrate
|
- Pitt-Hopkins syndrome, including: Pitt-Hopkins syndrome; Pitt-Hopkins-like syndrome
|
Novel |
NSD1 |
nuclear receptor binding SET domain protein 1 |
- PKMTs methylate histone lysines
|
|
- Beckwith-Wiedemann syndrome
- Sotos syndrome and Weaver syndrome
|
Novel |
PPP1R21 |
protein phosphatase 1 regulatory subunit 21 |
|
|
|
Novel |
STON1 |
stonin 1 |
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
|
|
|
BAIAP2 |
BAR/IMD domain containing adaptor protein 2 |
- Regulation of actin dynamics for phagocytic cup formation
- Regulation of actin dynamics for phagocytic cup formation
- VEGFA-VEGFR2 Pathway
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate WASPs and WAVEs
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
|
|
|
|
BCL2 |
BCL2 apoptosis regulator |
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-4 and Interleukin-13 signaling
- The NLRP1 inflammasome
- Estrogen-dependent gene expression
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
- Paclitaxel docosahexaenoic acid
- Apoptone
- Glycine betaine
- Eribulin
- Dexibuprofen
- Isosorbide
- Venetoclax
- Obatoclax
- Navitoclax
|
- Choriocarcinoma
- Gastric cancer
- Chronic lymphocytic leukemia (CLL)
- Small cell lung cancer
- Kaposi's sarcoma
- Nasopharyngeal cancer
- Cervical cancer
|
|
BCL2L1 |
BCL2 like 1 |
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-4 and Interleukin-13 signaling
- The NLRP1 inflammasome
- RAS processing
- STAT5 activation downstream of FLT3 ITD mutants
|
- 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID
- Isosorbide
- Gossypol
|
|
|
BDKRB1 |
bradykinin receptor B1 |
- Peptide ligand-binding receptors
- G alpha (q) signalling events
- G alpha (i) signalling events
|
- Ramipril
- Captopril
- Zinc
- Enalaprilat
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
CCR4 |
C-C motif chemokine receptor 4 |
- Chemokine receptors bind chemokines
- G alpha (i) signalling events
|
|
|
|
CERT1 |
ceramide transporter 1 |
|
|
|
|
CHRM4 |
cholinergic receptor muscarinic 4 |
- Muscarinic acetylcholine receptors
- G alpha (i) signalling events
|
- Ziprasidone
- Amitriptyline
- Olanzapine
- Metixene
- Terfenadine
- Clozapine
- Doxylamine
- Trihexyphenidyl
- Procyclidine
- Loxapine
- Carbamoylcholine
- Hyoscyamine
- Meperidine
- Imipramine
- Darifenacin
- Nortriptyline
- Amoxapine
- Cinnarizine
- Atropine
- Nicardipine
- Paroxetine
- Homatropine methylbromide
- Trimipramine
- Scopolamine
- Benzquinamide
- Propiomazine
- Tropicamide
- Brompheniramine
- Maprotiline
- Methantheline
- Bethanechol
- Tolterodine
- Promethazine
- Pilocarpine
- Doxepin
- Desipramine
- Ketamine
- Quetiapine
- Aripiprazole
- Chlorprothixene
- Methotrimeprazine
- Tiotropium
- Solifenacin
- Isopropamide
- Acetylcholine
- ALKS 27
- Fesoterodine
- Hexocyclium
- Aclidinium
- Umeclidinium
- Trimebutine
- Dosulepin
- Etoperidone
- Homatropine
- Thonzylamine
- Revefenacin
- Propiverine
- Rociverine
- Aripiprazole lauroxil
|
|
|
CLN8 |
CLN8 transmembrane ER and ERGIC protein |
|
|
- Neuronal ceroid lipofuscinosis, including: Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1); Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2); Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3); Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4); LINCL variant (CLN5, CLN6, CLN7, CLN8); Batten Disease variant (CLN9); Congenital NCL (CLN10)
- Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
|
|
CNTNAP1 |
contactin associated protein 1 |
|
|
|
|
CRMP1 |
collapsin response mediator protein 1 |
- CRMPs in Sema3A signaling
|
|
|
|
CYSLTR2 |
cysteinyl leukotriene receptor 2 |
- Glucagon signaling in metabolic regulation
- Leukotriene receptors
- G alpha (q) signalling events
- G alpha (s) signalling events
- Glucagon-type ligand receptors
- ADORA2B mediated anti-inflammatory cytokines production
- LTC4-CYSLTR mediated IL4 production
|
- Nedocromil
- Leukotriene C4
- Leukotriene D4
|
|
|
DRD2 |
dopamine receptor D2 |
|
- Amphetamine
- Ziprasidone
- Cabergoline
- Ropinirole
- Olanzapine
- Clozapine
- Thiethylperazine
- Sulpiride
- Loxapine
- Remoxipride
- Pramipexole
- Promazine
- Prochlorperazine
- Droperidol
- Imipramine
- Chlorpromazine
- Buspirone
- Haloperidol
- Triflupromazine
- Nortriptyline
- Amoxapine
- Lamotrigine
- Cinnarizine
- Lisuride
- Fluphenazine
- Thioridazine
- Ergotamine
- Apomorphine
- Paroxetine
- Trimipramine
- Risperidone
- Propiomazine
- Minaprine
- Trifluoperazine
- Perphenazine
- Flupentixol
- Amantadine
- Mesoridazine
- Maprotiline
- Dopamine
- Carphenazine
- Memantine
- Ergoloid mesylate
- Acetophenazine
- Promethazine
- Pimozide
- Desipramine
- Escitalopram
- Domperidone
- Pergolide
- Bromocriptine
- Ketamine
- Quetiapine
- Metoclopramide
- Levodopa
- Aripiprazole
- Chlorprothixene
- Paliperidone
- Yohimbine
- Methotrimeprazine
- Alizapride
- Rolicyclidine
- Acepromazine
- Molindone
- Pipotiazine
- Thioproperazine
- Thiothixene
- Zuclopenthixol
- Aniracetam
- Fluspirilene
- Tetrabenazine
- Brasofensine
- Bifeprunox
- Bicifadine
- Itopride
- Iloperidone
- Rotigotine
- Pimavanserin
- BL-1020
- ACP-104
- Amitifadine
- Cariprazine
- Lumateperone
- YKP-1358
- Sertindole
- Mianserin
- Asenapine
- Ocaperidone
- Amisulpride
- Sarizotan
- Sumanirole
- Lurasidone
- Perospirone
- Bromopride
- Quinagolide
- Brexpiprazole
- Etoperidone
- AS-8112
- Blonanserin
- Melperone
- Zotepine
- Pipamperone
- Dihydro-alpha-ergocryptine
- Epicriptine
- Pardoprunox
- Tetrahydropalmatine
- Piribedil
- Raclopride
- JNJ-37822681
- Tiapride
- Dihydroergocristine
- Aripiprazole lauroxil
|
|
|
ERBB2 |
erb-b2 receptor tyrosine kinase 2 |
- Signaling by ERBB2
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Downregulation of ERBB2:ERBB3 signaling
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Sema4D induced cell migration and growth-cone collapse
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Constitutive Signaling by Overexpressed ERBB2
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
|
- Trastuzumab
- Lapatinib
- IGN311
- Trastuzumab emtansine
- Varlitinib
- AV-412
- Pertuzumab
- Afatinib
- Tucatinib
- Tesevatinib
- Fostamatinib
- Brigatinib
- Margetuximab
- Zanubrutinib
|
- Choriocarcinoma
- Pancreatic cancer
- Gastric cancer
- Bladder cancer
- Endometrial Cancer
- Ovarian cancer
- Cholangiocarcinoma
- Breast cancer
- Cervical cancer
|